Complicated community acquired pneumonia in children prior to the introduction of the pneumococcal conjugated vaccine

Aviv D. Goldbart, Eugene Leibovitz, Nurith Porat, Noga Givon-Lavi, Ido Drukmann, Asher Tal, David Greenberg

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

Increasing prevalence of pleural empyema (PE) complicating community acquired pneumonia (CAP) is reported worldwide. We compared hospitalized children with PE or non-purulent pleural effusion (NP-PEF) prior to the inclusion of the pneumococcal conjugated vaccine (PCV7) in the Israeli immunization schedule. We conducted a retrospective analysis of medical files of all children < 18 y of age hospitalized with either PE or NP-PEF and CAP during 1990-2002. 75 children with NP-PEF and 37 with PE were identified. PE annual incidence increased from 0.5 in 1990 to 4.2 per 100,000 children in 2002. Higher WBC and absolute neutrophils counts were found in sera and pleural fluid of PE. The leading pathogens included Streptococcus pneumoniae (42%, all penicillin-susceptible) and Staphylococcus aureus (23%, all methicillin-susceptible). Blood cultures were positive only in children with PE (12/37, 32.4%). Patients with PE presented with higher respiratory rate and required longer hospitalization, more PICU admission, and more patients needed mechanical ventilation. PE prevalence increased in southern Israel during the study period. Streptococcus pneumoniae (62.5% serotype 1) was the most common pathogen causing PE before the introduction of PCV7. Future introduction of PCV7 or equivalents in the immunization schedule may impact clinical presentation and epidemic trends and will require future consideration.

Original languageEnglish
Pages (from-to)182-187
Number of pages6
JournalScandinavian Journal of Infectious Diseases
Volume41
Issue number3
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Dive into the research topics of 'Complicated community acquired pneumonia in children prior to the introduction of the pneumococcal conjugated vaccine'. Together they form a unique fingerprint.

Cite this